MedicinesFAQ

Avdoralimab Uses, Dosage, Side Effects and more

Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).

Attribute Details
Trade Name Avdoralimab
Generic Avdoralimab
Avdoralimab Other Names Avdoralimab
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am
   

How Avdoralimab works

Avdoralimab binds and inhibits C5a receptors (C5aR) expressed on myeloid-derived suppressor cells and neutrophils. C5a is often associated with tumors; by blocking the binding of C5a to C5aR, Advoralimab reduces the activation of MDSC and neutrophils in tumor microenvironments, thus exhibiting anti-tumor activity.

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.